News
HRMY ▼ -1.5% - Harmony Biosciences Holdings, Inc.
HRMY ▼ -1.5% - Harmony Biosciences Holdings, Inc.
$HRMY - Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
04-NOV-2026 07:30 AM ET
Share this post
More filings for $HRMY
HRMY ▼ -5.8% - Harmony Biosciences Holdings, Inc.Nov 4, 2026HRMY - Harmony Biosciences Holdings, Inc. - SEC Filing Update (27-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 27, 2026HRMY ▲ +0.2% - Harmony Biosciences Holdings, Inc.Oct 20, 2026HRMY ▼ -1.0% - Harmony Biosciences Holdings, Inc.Oct 12, 2026HRMY ▼ -0.1% - Harmony Biosciences Holdings, Inc.Sep 3, 2026$HRMY SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $HRMY filing history →💬 Comments
Loading comments…
Leave a comment